Tirzepatide (Copy)

1. Complete a Medical Intake Form: Upon registering, you will be asked to fill out a detailed medical intake form, which gathers your health history and relevant information about your weight loss goals.
2. Review by a Physician: Once your intake form is submitted, one of Healthon’s licensed physicians will review your information to determine your medical eligibility for the program. Depending on your state’s telehealth regulations, this review will be conducted either through a SYNC (live) or ASYNC (offline) telehealth visit.
3. Approval and Notification: If you are approved, you will receive a notification of your eligibility for the program, and your prescription for either Semaglutide or Tirzepatide will be issued.
4. Medication Shipment: Once your prescription is approved, your medication will be shipped directly to your home. You will receive tracking information to monitor the delivery.

The Healthon Weight Loss Program offers two highly effective GLP-1 medications:


• Semaglutide (Generic Ozempic®/Wegovy®): A GLP-1 receptor agonist, FDA-approved for weight management and type 2 diabetes.
• Tirzepatide (Generic Mounjaro®): A dual GLP-1 and GIP receptor agonist, FDA-approved for type 2 diabetes and used off-label for weight loss.


Both medications are administered via injection and work to promote weight loss by reducing appetite, enhancing feelings of fullness, and regulating blood sugar levels.

Healthon is committed to providing affordable pricing for all weight loss treatments. Here’s the pricing breakdown for the program:



Commercial-Grade Semaglutide: Starting at $275/month.
Commercial-Grade Tirzepatide: Starting at $395/month.


These prices include consultations, medications, and ongoing support. There are no hidden fees, and Healthon’s Price Match Guarantee ensures you receive the most competitive rates for your weight loss program.

Commercial-grade GLP-1 medications are FDA-approved and manufactured by large pharmaceutical companies, ensuring strict safety, efficacy, and consistency standards. These medications undergo rigorous quality control and are subject to FDA regulations.


Compounded versions are customized by pharmacies and may offer lower prices, but they do not undergo the same rigorous testing or have an FDA NDC number. Compounded medications may vary slightly in dosage or formulation, which can affect efficacy and safety.

Commercial-grade semaglutide is a medication that is manufactured in 503B outsourcing FDA-registered facilities and drug manufacturers. These facilities adhere to a much stricter Current Good Manufacturing Practices (cGMP) and undergo rigorous FDA reviews for safety, manufacturing process, raw ingredient efficacy, and quality. 
Commercial-grade semaglutide is produced on a large scale using advanced technologies, including robotic manufacturing and in-house testing, ensuring consistent quality and compliance with FDA standards in order to obtain approval and indicated National Drug Code (NDC).
In contrast, compounded semaglutide is formulated in 503A compounding pharmacies specifically to meet individual patient needs, often during drug shortages. While compounded semaglutide uses the same active ingredient, it does not undergo the same FDA approval process or extensive quality testing as commercial-grade semaglutide.

U.S. Food and Drug Administration (FDA). (2021). Compounded drugs: Questions and answers.

 Compounded semaglutide refers to a customized medication formulated by a 503A compounding pharmacy, which is registered and regulated by the state board of pharmacy and adheres to both FDA and state regulations, ensuring they meet high-quality standards. These pharmacies are legally permitted to produce compounded versions of FDA-approved drugs when they are on FDA drug shortlist. This ensures that patients continue to have access to and benfit from the essential medications when commercially manufactured drugs are unavailable.
At Healthon, we have conducted extensive due diligence and partnered exclusively with reputable, fully compliant, US-based compounding pharmacies. These pharmacies utilize the highest quality semaglutide base, which is the same active ingredient found in FDA-approved medications like Ozempic and Wegovy.
Please note that compounded medications are not subject to the same rigorous reviews and manufacturing practices mandated by the FDA for commercially available and generic versions.

U.S. Food and Drug Administration (FDA). (2021). Compounded drugs: Questions and answers.

Semaglutide and Tirzepatide are GLP-1 receptor agonists that help regulate blood sugar levels and reduce appetite. By mimicking the action of the glucagon-like peptide-1 (GLP-1) hormone, these medications slow gastric emptying, increase the feeling of fullness, and reduce calorie intake, resulting in significant weight loss over time.


• Semaglutide: Primarily approved for type 2 diabetes and weight management, it works by increasing insulin secretion and reducing appetite.
• Tirzepatide: Also a dual agonist that targets both GLP-1 and GIP receptors, which helps regulate blood sugar more effectively and may lead to greater weight loss in comparison to Semaglutide.

Wilding, J. P. H., et al. (2021). Once-weekly Semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.

Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387, 205-216.

Addressing obesity is crucial because it significantly impacts both physical health and quality of life. Untreated obesity is linked to a number of serious health conditions, including:


• Cardiovascular disease: Obesity increases the risk of high blood pressure, heart attacks, and strokes.
• Type 2 diabetes: Excess body fat, especially around the abdomen, contributes to insulin resistance and can lead to type 2 diabetes.
• Joint and mobility issues: Extra weight can strain joints, leading to conditions like osteoarthritis.
• Mental health: Obesity is often associated with low self-esteem, depression, and anxiety due to societal stigma and body image concerns.


By addressing obesity with safe and effective medications, patients can reduce their risk of these health issues and improve their overall well-being.

Apovian, C. M., et al. (2015). Pharmacological management of obesity: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 100(2), 342-362.

World Health Organization (2021). Obesity and overweight.

GLP-1 medications like Semaglutide and Tirzepatide are highly effective for weight loss due to their ability to mimic the effects of the glucagon-like peptide-1 (GLP-1) hormone. Here’s why they work so well:


• Appetite Regulation: GLP-1 slows the rate at which the stomach empties, helping you feel full longer and reducing overall calorie intake.
• Insulin Sensitivity: These medications improve insulin sensitivity, leading to better blood sugar control, which helps reduce fat storage.
• Hormonal Action: By acting on the hypothalamus, the part of the brain that controls hunger, GLP-1 medications help reduce food cravings and binge eating behaviors.


In clinical trials, patients using Semaglutide have shown an average weight loss of 15-18%, while Tirzepatide has demonstrated up to 20-22% weight loss in some cases.

Wilding, J. P. H., et al. (2021). Once-weekly Semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.

Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387, 205-216.

Both medications are highly effective for weight loss, but there are some key differences:


• Semaglutide (Ozempic/Wegovy): Primarily acts as a GLP-1 receptor agonist and has been shown to result in around 15-18% weight loss over time for many patients.
• Tirzepatide (Mounjaro): Targets both GLP-1 and GIP receptors, which can lead to more robust results. Studies have shown that Tirzepatide can lead to up to 20-22% weight loss, making it slightly more effective for some patients.

Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387, 205-216.

Results from the Healthon Weight Loss Program vary depending on the individual, but most patients begin to see noticeable weight loss within the first 4-12 weeks of treatment. GLP-1 medications like Semaglutide and Tirzepatide are typically administered once weekly, and gradual, sustained weight loss occurs over several months.


On average, patients experience:


• 5-10% weight loss within the first 3 months.
• Up to 15-22% weight loss after 6-12 months of continuous use.


Consistency in treatment, along with lifestyle changes such as diet and physical activity, can further enhance and maintain weight loss.

Wilding, J. P. H., et al. (2021). Once-weekly Semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.

Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387, 205-216.

Most side effects are mild and tend to subside over time, but more serious side effects may occur in rare cases.


Common Side Effects:


• Nausea: This is the most common side effect and usually occurs when starting the medication or after increasing the dose. It generally improves over time.
• Vomiting
• Diarrhea
• Constipation
• Indigestion
• Decreased appetiteLess Common but Serious Side Effects:


• Hypoglycemia (low blood sugar): Especially when used in combination with other diabetes medications like insulin.
• Pancreatitis: In rare cases, GLP-1 medications have been associated with inflammation of the pancreas.
• Gallbladder issues: Including gallstones.
• Kidney problems: May lead to dehydration and worsen kidney function in patients with pre-existing kidney conditions.


Injection Site Reactions:


• Redness or irritation at the injection site is possible but usually mild.

FDA Prescribing Information for Semaglutide (Ozempic)

FDA Prescribing Information for Tirzepatide (Mounjaro)

Trujillo, J. M., & Nuffer, W. (2020). GLP-1 receptor agonists for type 2 diabetes: Latest evidence and clinical considerations. Therapeutic Advances in Chronic Disease, 11, 2040622320968755.